ストックスクリーナーアプリを入手
0.0853
5.22%
-0.0047
アフターアワーズ：
.09
0.0047
+5.51%
前日終値:
$0.09
開ける：
$0.0831
24時間の取引高:
14.09M
Relative Volume:
1.72
時価総額：
$9.50M
収益：
-
当期純損益:
$-37.28M
株価収益率:
-0.1236
EPS:
-0.69
ネットキャッシュフロー:
$-32.24M
1週間 パフォーマンス:
+2.16%
1か月 パフォーマンス:
-7.68%
6か月 パフォーマンス:
-86.88%
1年 パフォーマンス:
-94.92%
1日の値動き範囲:
$0.0831
$0.0948
1週間の範囲:
$0.077
$0.0948
52週間の値動き範囲:
$0.077
$2.57
Eyenovia Inc Stock (EYEN) Company Profile
EYEN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EYEN
Eyenovia Inc
|
0.0853 | 9.50M | 0 | -37.28M | -32.24M | -0.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Eyenovia Inc Stock (EYEN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-18 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2021-03-01 | 開始されました | Northland Capital | Outperform |
| 2020-02-03 | ダウングレード | Oppenheimer | Outperform → Perform |
Eyenovia Inc (EYEN) 最新ニュース
Stay Ahead in Ophthalmology: Strategic Market Insights for Myopia Assessment & Forecasting | DelveInsight - GlobeNewswire Inc.
Eyenovia faces Nasdaq delisting over low stock price By Investing.com - Investing.com Australia
Eyenovia faces Nasdaq delisting over low stock price - Investing.com
Eyenovia’s $1.9M Offering to Boost Optejet Development - TipRanks
Form 424B5 EYENOVIA, INC. - StreetInsider.com
SEC Form 424B5 filed by Eyenovia Inc. - Quantisnow
Eyenovia announces pricing of $1.9M registered direct offering - MSN
Eyenovia secures $1.9 million in direct offering By Investing.com - Investing.com Canada
Eyenovia secures $1.9 million in direct offering - Investing.com
Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering - GlobeNewswire
Eyenovia Announces $1.9M Direct Offering to Fund Optejet Development, Strategic Growth - StockTitan
These Numbers Show Just How Powerful Eyenovia Inc (NASDAQ: EYEN) Stock Is - Stocks Register
Eyenovia’s Direct Offering to Support Strategic Initiatives - TipRanks
Eyenovia secures $1.3 million in direct offering By Investing.com - Investing.com South Africa
Eyenovia (NASDAQ:EYEN) Enters Into First Amendment to Loan Agreement and Subscription Agreement - Defense World
Eyenovia defers loan payments, issues equity to lenders - Investing.com
Eyenovia defers loan payments, issues equity to lenders By Investing.com - Investing.com Canada
Eyenovia Slumps On Pricing Of Registered Direct Offering - Nasdaq
Eyenovia Restructures Finances and Leadership Team - TipRanks
Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Offering - The Manila Times
Eyenovia secures $1.3 million in direct offering - Investing.com
Eyenovia Raises $1.3M in Direct Offering at $0.1076 Per Share with Warrants | EYEN Stock News - StockTitan
Eyenovia taking additional actions to reduce personnel-related costs by over 70% - Yahoo Finance
Eyenovia secures debt payment deferral from Avenue Capital By Investing.com - Investing.com Nigeria
Eyenovia Continues to Evaluate Broad Range of Strategic Alternatives to Maximize Stakeholder Value - Marketscreener.com
Eyenovia secures debt payment deferral from Avenue Capital - Investing.com
Eyenovia Provides Update on Restructuring Efforts - The Manila Times
Eyenovia reports low cash reserves; in talks for debt restructuring By Investing.com - Investing.com South Africa
Eyenovia reports low cash reserves; in talks for debt restructuring - Investing.com
Eyenovia Stock Tumbles on Termination of Phase III Myopia Study - MSN
Eyenovia downgraded to Neutral from Buy at H.C. Wainwright - Yahoo Finance
William Blair Reaffirms “Market Perform” Rating for Eyenovia (NASDAQ:EYEN) - Defense World
Eyenovia (NASDAQ:EYEN) Earns Hold Rating from Brookline Capital Management - Defense World
Eyenovia stock plummets following Phase III myopia trial failure - Clinical Trials Arena
Black Friday for Eyenovia as shares fall 70% - The Pharma Letter
Eyenovia stock downgraded to Neutral, price target set on challenges By Investing.com - Investing.com UK
Eyenovia halts myopia study after missing primary endpoint - Investing.com India
Eyenovia, Inc. Provides Update on Phase 3 CHAPERONE Study - Marketscreener.com
Eyenovia to Cut 50% of Workforce After Phase 3 Study Disappoints - MarketWatch
Eyenovia to end eye drug study, cut 50% of its workforce - Reuters
Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline - AOL
Eyenovia Shares Plumb New Depths After Study Failure - MarketWatch
Eyenovia Shares Plummet 70% After It Drops Lead Program - BioSpace
Eyenovia Inc (EYEN) 財務データ
収益
当期純利益
現金流量
EPS
Eyenovia Inc (EYEN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Rowe Michael M | Chief Executive Officer |
Aug 26 '24 |
Buy |
0.57 |
50,000 |
28,500 |
82,927 |
| Grant Stuart M. | 10% Owner |
Jul 02 '24 |
Buy |
0.66 |
1,515,151 |
1,000,000 |
10,914,153 |
| Grant Stuart M. | 10% Owner |
Mar 28 '24 |
Buy |
0.98 |
100,000 |
98,000 |
5,430,715 |
| Grant Stuart M. | 10% Owner |
Mar 19 '24 |
Buy |
1.23 |
50,000 |
61,500 |
5,330,715 |
| Grant Stuart M. | 10% Owner |
Mar 08 '24 |
Buy |
1.58 |
10,717 |
16,911 |
5,280,715 |
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):